Showing 7831-7840 of 10261 results for "".
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas
- FDA approves Impavido to treat tropical disease leishmaniasishttps://practicaldermatology.com/news/20140320-fda_approves_impavido_to_treat_tropical_disease_leishmaniasis/2459308/The US Food and Drug Administration approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and
- Sciton Announces Launch of Halo at AAD Annual Meetinghttps://practicaldermatology.com/news/20140320-sciton_announces_launch_of_halo_at_aad_annual_meeting/2459309/
- Ferndale Healthcare Announces Partnership with Colon Cancer Alliancehttps://practicaldermatology.com/news/20140318-ferndale_healthcare_announces_partnership_with_colon_cancer_awareness/2459313/Ferndale Healthcare's RectiCare® Cream, intended to resolve all discomfort from rectal and anal conditions such as hemorrhoids and anal fissures, urges colon screening for cancer before individuals reach for their brand. The brand wants to promote individuals to not rush to treat when bleeding an
- Antares Pharma Announces LEO Pharma's Launch of Otrexup (Methotrexate) Injection for Adults with Psoriasishttps://practicaldermatology.com/news/20140311-antares_pharma_announces_leo_pharmas_launch_of_otrexup_methotrexate_injection_for_adults_with_psoriasis/2459320/Antares Pharma, Inc. announced LEO Pharma's launch of Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. "We are very pleased that
- Upcoming Events to Educate PAs and NPs about Psoriasishttps://practicaldermatology.com/news/20140310-upcoming_events_to_educate_pas_and_nps_about_psoriasis/2459321/Nurse practitioners and physician assistants aiming to deepen their understanding of psoriasis can attend upcoming events sponsored by the The National Psoriasis Foundation. The Nurse Practitioner Psoriasis Symposium, a joint symposium from the
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/